Tag Archive for: Vice President Clinical Affairs

Jing Xie, PhD, MS, Joins MDIC as Vice President, Clinical Affairs

Former Vice President, Global Clinical Affairs, Zimmer Biomet

Life Science Partner recruited Jing Xie, PhD, MS, former Vice President, Global Clinical Affairs for Zimmer Biomet to become the Medical Device Innovation Consortium’s (MDIC) first Vice President, Clinical Affairs.

MDIC is the first-ever public-private partnership (PPP) created with the sole objective of advancing medical device regulatory science to expedite development, assessment, and review of innovative medical technologies. The overall mission of the MDIC is to support the FDA’s vision to achieve first in the world patient access in the US and to assure the safety and effectiveness of medical devices through the Total Product Life Cycle.

Xie takes on her new role at the MDIC after having oversight of approximatively 300 clinical projects worldwide for Zimmer Biomet. She possesses a highly successful track record in the orthopedic industry for delivering on objectives, while maintaining effective collaboration with internal and external stakeholders.

“With a global understanding around clinical trial management including data integration for regulatory agencies across the US, Europe and Asia, Xie is a well-seasoned leader to execute the clinical affairs initiatives at the MDIC,” states Tom Callaway, MD, Founder and President of Life Science Partner.

Jing Xie earned her Bachelor of Science Degree in Analytical Chemistry from Xiamen University in China and completed her PhD in Materials Science from the University of Alabama. She holds an MS in Computer Science from Purdue University and an MS in Chemistry from the University of Alabama.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Barb DeBaun, RN, MSN Recruited to Vestagen as Consulting Vice President, Clinical Affairs

Improvement Advisor for Cynosure Health Joins Vestagen

Life Science Partner recruited Barb DeBaun, RN, MSN, CIC, to become Vice President, Clinical and Regulatory Affairs for Vestagen Technical Textiles, Inc.

DeBaun joins Vestagen after serving as an Improvement Advisor for Cynosure Health where she provided vision and leadership in the development, implementation and facilitation of performance improvement initiatives for healthcare organizations.

In her new role at Vestagen, DeBaun will serve as the senior clinical leader for The Company overseeing clinical direction, product strategy, medical affairs and key thought leader development. “DeBaun’s passion for protecting the healthcare worker from infection while providing quality care makes her a natural fit for Vestagen’s VP of Clinical and Regulatory Affairs,” states Tom Callaway, MD, Founder and President of Life Science Partner.

DeBaun earned her Bachelor of Science in Nursing from Pace University and her Master of Science in Nursing from San Francisco State University. DeBaun is an active member of APIC having served as the chair of the 2012 APIC Annual Conference Committee and as a member of the APIC Education Committee and the APIC Practice Guidance Council. In 2008, she was selected as Infection Control Today‘s Educator of the Year.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by

Steve Hamburger, PhD, joins Exoxemis, Inc. as Vice President, Clinical and Regulatory Affairs

Life Science Partner recruits former Oncology Regulatory Officer for Johnson & Johnson, Pharmaceutical and Research & Development.

Life Science Partner announces the recruitment of Steve Hamburger, a global regulatory and drug development executive, to Exoxemis, Inc.

Exoxemis is an early-stage biopharmaceutical research and development company focused on prevention and treatment of serious infections and the significant and growing problem of microbial drug resistance.  The company’s myeloperoxidase (MPO) technology is a versatile platform that can be leveraged into multiple product areas, including medical, biodefense, industrial, veterinary, disinfectant, and agricultural applications.

In Hamburger’s most recent role at J & J, he was responsible for a cross-functional regulatory and drug development team and served as a global regulatory officer for the Oncology and Hematology division.  His portfolio included the key biologic PROCRIT.  Previously, he served in a similar role as the strategic and operational leader for the anti-cancer drug DOXIL.  Prior to his tenure at J & J, Hamburger was Senior Regulatory Research Scientist, Oncology and US Regulatory Affairs for Eli Lilly and Company.

“Steve is an experienced regulatory strategist with a broad therapeutic background in the pharmaceutical industry including the areas of infectious diseases, cardiology and oncology,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He’s a passionate and self-directed individual with a long track record of successful interactions with key global health authorities that will greatly benefit Exoxemis’ platform and opportunity.”

Hamburger received his Bachelor of Science degree in General Science and Biochemistry from the University of Iowa in Iowa City.   He earned a Master of Science in Biology from Butler University in Indianapolis, Indiana and his PhD in Pharmacology and Toxicology from the Indiana University School of Medicine.

/0 Comments/by